Tesamorelin: a beginner's guide to the belly-fat peptide

Key takeaways

• Tesamorelin is a lab-made copy of GHRH (growth-hormone-releasing hormone), given as a daily shot under the skin. It signals your own pituitary to release more growth hormone, which then raises IGF-1 .
• It is the one FDA-approved drug in this group (sold as Egrifta), but the approval is narrow: reducing excess belly fat in adults with HIV-related lipodystrophy. The label says outright it is not for weight loss because it is weight-neutral .
• In the pivotal HIV trial, deep belly fat (visceral fat) dropped 15.2 percent over 26 weeks while IGF-1 jumped 81.0 percent . Those numbers come only from HIV patients, not healthy adults.
• The effect is not durable. When people stopped, their visceral fat climbed back toward baseline, so it only holds while you keep taking it .
• The label raises IGF-1 and states the long-term effects of that are unknown, so it requires IGF-1 monitoring. It is hard-contraindicated in pregnancy, active cancer, and a disrupted pituitary axis .
• It is a prescription drug and is banned for tested athletes at all times, under WADA category S2 (growth-hormone-releasing hormone analogs) .

The short version: a real drug with a very narrow approval

An approved prescription drug showing up on a research-peptide list looks odd at first. The reason is that the approval covers one small group, adults with HIV-associated lipodystrophy, and everyone else buying it (for stubborn belly fat, for a growth-hormone nudge) is using it off-label, often from a research vial rather than a pharmacy . It is the same molecule either way, but the footing is very different.

What it is: a GHRH copy that nudges your own growth hormone

Tesamorelin is a synthetic version of GHRH, short for growth-hormone-releasing hormone, the natural signal your brain sends the pituitary gland to release growth hormone . It is a stabilized 44-amino-acid peptide, built so it survives longer in the body than the natural signal does.

It does not put growth hormone into you the way injecting HGH does. It tells your own pituitary to release more, which then raises IGF-1, the downstream growth factor that carries out much of growth hormone's work . It is taken as a small daily injection under the skin of the abdomen .

What people use it for: stubborn belly fat, mostly

In the approved setting, tesamorelin treats the deep abdominal fat that some people with HIV accumulate, often on older antiretroviral therapy . Off-label, the reported use is almost entirely about one thing: stubborn visceral fat, the deep belly fat that sits around the organs and does not shift with dieting.

The common pattern is someone who has already leaned out through training, a GLP-1, or plain diet, and is left with a belly that will not go. Tesamorelin gets used as a months-long finisher for that. It also gets grouped with the growth-hormone-secretagogue peptides (ipamorelin, CJC-1295), where it is often the higher-evidence pick because it actually has a phase 3 readout behind it.

That phase 3 readout, though, was in HIV patients. Almost every reported belly-fat win outside that group is anecdote, user reports and habit, not trial results, and that is worth knowing before you commit months to it.

What the science shows: real phase 3 data, but only in HIV patients

This is where tesamorelin stands apart from most research peptides: it has genuine human phase 3 evidence. The catch is how narrow it is.

The pivotal trial (Falutz and colleagues, 2007) randomized 412 adults with HIV-associated abdominal fat to tesamorelin or placebo for 26 weeks. The numbers:

A pooled analysis of both phase 3 trials (806 patients) confirmed a visceral-fat treatment effect of about 15 percent, with no clinically meaningful change in blood sugar across the study .

Two things temper all of it. First, the benefit is not durable: people switched from tesamorelin to placebo re-accumulated visceral fat back toward baseline, so it behaves as ongoing therapy, not a one-time cut . Second, every one of those trials enrolled only HIV patients with lipodystrophy , so using it for ordinary belly fat in someone without HIV means stepping outside the population the evidence actually covers.

The catch: real risk sheet, and off-label skips the monitoring

• Sugar and IGF-1 are the two numbers to watch. The label warns it can cause glucose intolerance (a step toward diabetes) and requires IGF-1 monitoring, since sustained high IGF-1 is the biomarker prescribers track and the reason to reduce or stop .
• GH-axis side effects show up early and physically: joint pain (arthralgia), swelling (peripheral edema), muscle aches, and carpal-tunnel-type wrist symptoms are among the reactions the label names .
• Injection-site reactions are common, redness, itching, pain, bruising, or swelling, so rotate sites around the abdomen .
• Allergic reactions happen. Stop and get prompt care for rash, hives, swelling of the face or throat, trouble breathing, flushing, faintness, or a racing heart .
• It does not lower scale weight. The label says outright it is not for weight loss because it is weight-neutral, so if the goal is pounds on the scale, this is the wrong tool .
• The fat comes back. Stop dosing and visceral fat drifts toward baseline, so any benefit means staying on it, and staying exposed to everything above .
• Egrifta WR and Egrifta SV are not interchangeable. They are different strengths (1.28 mg vs 2 mg) with different mixing and storage steps, so a dose or a routine from one does not carry to the other .
• Off-label in a healthy adult is unproven ground. The trials that earned the approval were all in HIV-associated lipodystrophy, and a research vial is not the studied, pharmacy-dispensed product .

How people take it, and the two numbers not to skip

If you are going to use it, the goal is to stay as close to the studied version as you can. Tesamorelin is a small subcutaneous injection into the abdomen, once daily . Injectable tesamorelin ships as a freeze-dried powder you reconstitute with liquid before drawing a dose, and getting the concentration right is the step every later dose depends on.

The one thing worth building in from day one is monitoring. IGF-1 and a fasting glucose (or HbA1c) are the two lab values the trials and the label were built around, and they are exactly what off-label users tend to skip . Get a baseline before you start and recheck on it. And because a research vial is not the pharmacy product, a third-party certificate of analysis is the one quality lever you actually control.

Where to go deeper

This guide is the on-ramp. For the full trial-by-trial picture, tesamorelin and visceral fat walks the phase 3 data, the liver-fat findings, and the monitoring in detail. If you are comparing it to the other growth-hormone-axis peptides, CJC-1295 and ipamorelin versus pharmaceutical HGH lays out how the secretagogues differ, and the AOD-9604 reality check covers another fat-loss fragment with a much thinner record. For the wider scene, the most in-demand peptides of 2026 puts tesamorelin in context. The tesamorelin library entry is the quick reference for dosing ranges, storage, and sources.

How we sourced this, and the fine print

Every claim here is pinned to a published source: the FDA label on DailyMed, the phase 3 trials, the review on what happens after stopping, the NIH LiverTox record, and the anti-doping literature. Where the human data stops at HIV patients, this guide says so instead of stretching it.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these guides: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 6 entries, all primary or authoritative (the FDA label via DailyMed, PubMed trials, PubMed Central, and NIH LiverTox), last reviewed 2026-07-13.

Related tools

• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.